急性髓系白血病患者恶性细胞群中S100A9高表达细胞占比对化疗反应及预后的评估价值

doi:10.3969/j.issn.1006-5725.2026.13.008

Abstract

Abstract:

Objective To investigate the clinical significance of the proportion of S100A9-high-expressing cells in the malignant cell population of acute myeloid leukemia （AML）， and to analyze its association with chemotherapeutic response and patient prognosis， so as to provide evidence for the identification and prognostic evaluation of high-risk AML patients. Methods Survival curves were initially generated using the BeatAML and TCGA datasets based on S100A9 transcript expression levels. Subsequently， a total of 80 patients with AML， consisting of 44 chemotherapy-sensitive cases and 36 chemotherapy-resistant cases， along with 10 healthy donors， were recruited. Multiparameter flow cytometry was carried out to assess the proportion of S100A9-high-expressing cells within the pre-defined AML malignant cell population. The relationships between this proportion and post-chemotherapy response as well as survival outcomes were analyzed. Immunocytochemistry and immunohistochemistry were further employed for validation. Results Survival analysis based on the overall expression of S100A9 mRNA revealed no statistically significant difference in either the TCGA or BeatAML dataset. Nevertheless， the proportion of malignant cells with high S100A9 expression was significantly higher in non-remission AML patients compared to those who achieved remission. The area under the receiver operating characteristic （ROC） curve was 0.765， and the optimal cutoff value was determined to be 12.65%. Patients characterized by a high proportion of malignant cells with high S100A9 expression， as defined by this cutoff， exhibited poorer survival outcomes and an unfavorable prognosis. Conclusions The proportion of S100A9-high-expressing malignant cells in AML could serve as a potential prognostic indicator. In comparison to the overall S100A9 expression， this parameter might be more effective in identifying high-risk AML patients.

Key words: acute myeloid leukemia, S100A9, chemotherapeutic response, prognosis

CLC Number:

R733.71

Tai XIE,Junzhao WAN,Min ZHANG,Dan MA. Evaluation value of the proportion of S100A9-high-expressing cells in the malignant cell population for chemotherapy response and prognosis in patients with acute myeloid leukemia[J]. The Journal of Practical Medicine, 2026, 42(13): 2331-2339.

Figures/Tables 6

Fig.1

Fig.2

Tab.1

Fig.3

Fig.4

Fig.5

References 23

[1]	强晓，耿贝贝，刘四喜，等. 转录组学技术在急性白血病诊治中的应用研究进展［J］. 实用医学杂志， 2023， 39（22）： 3010-3014. doi：10.3969/j.issn.1006-5725.2023.22.027 . doi: 10.3969/j.issn.1006-5725.2023.22.027
[2]	DART A. Energizing leukaemia［J］. Nat Rev Cancer， 2025， 25（7）： 491. doi：10.1038/s41568-025-00842-7 . doi: 10.1038/s41568-025-00842-7
[3]	KANTARJIAN H， CHIFOTIDES H T， HADDAD F G， et al. The care and cure of the leukemias in 2026［J］. Am J Hematol， 2026， 101（4）： 807-831. doi：10.1002/ajh.70247 . doi: 10.1002/ajh.70247
[4]	NEWELL L F， COOK R J. Advances in acute myeloid leukemia［J］. BMJ， 2021： n2026. doi：10.1136/bmj.n2026 . doi: 10.1136/bmj.n2026
[5]	CHEN Y， OUYANG Y， LI Z， et al. S100A8 and S100A9 in cancer［J］. Biochim Biophys Acta BBA Rev Cancer， 2023， 1878（3）： 188891. doi：10.1016/j.bbcan.2023.188891 . doi: 10.1016/j.bbcan.2023.188891
[6]	MONDET J， CHEVALIER S， MOSSUZ P. Pathogenic roles of S100A8 and S100A9 proteins in acute myeloid and lymphoid leukemia： Clinical and therapeutic impacts［J］. Molecules， 2021， 26（5）： 1323. doi：10.3390/molecules26051323 . doi: 10.3390/molecules26051323
[7]	BOUSSI L， CAI S F， STEIN E M. Advances in menin inhibition in acute myeloid leukemia［J］. Trends Cancer， 2025， 11（9）： 889-900. doi：10.1016/j.trecan.2025.06.002 . doi: 10.1016/j.trecan.2025.06.002
[8]	CAO S， PAN C， HU X， et al. SLC44A1 promotes AML progression and chemoresistance by regulating the Notch signaling pathway［J］. Neoplasma， 2026， 73（1）： 26-36. doi：10.4149/neo_2025_250518n209 . doi: 10.4149/neo_2025_250518n209
[9]	FAN R， SATILMIS H， VANDEWALLE N， et al. Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia［J］. Blood Cancer J， 2023， 13： 188. doi：10.1038/s41408-023-00962-z . doi: 10.1038/s41408-023-00962-z
[10]	曾凤. BCL-2抑制剂维奈克拉联合PI3K抑制剂林普利塞对急性T淋巴细胞白血病Jurkat细胞的作用及机制研究［D］. 泸州：西南医科大学， 2025.
[11]	黄坤源，江克华，王庆. S100A9在肾脏疾病中的研究进展［J］. 实用医学杂志， 2024， 40（22）： 3251-3255. doi：10.3969/j.issn. 1006-5725.2024.22.022 . doi: 10.3969/j.issn. 1006-5725.2024.22.022
[12]	ZAVORKA THOMAS M E， JEON J Y， TALEBI Z， et al. Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia［J］. Blood Adv， 2021， 5（23）： 5041-5046. doi：10.1182/bloodadvances.2021005614 . doi: 10.1182/bloodadvances.2021005614
[13]	BÖTTCHER M， PANAGIOTIDIS K， BRUNS H， et al. Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset［J］. Blood Adv， 2022， 6（21）： 5685-5697. doi：10.1182/bloodadvances. 2021005938 . doi: 10.1182/bloodadvances. 2021005938
[14]	DE VEIRMAN K， DE BEULE N， MAES K， et al. Extracellular S100A9 protein in bone marrow supports multiple myeloma survival by stimulating angiogenesis and cytokine secretion［J］. Cancer Immunol Res， 2017， 5（10）： 839-846. doi：10.1158/2326-6066.cir-17-0192 . doi: 10.1158/2326-6066.cir-17-0192
[15]	LI X， LI Q， XIANG X， et al. The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms［J］. Cytokine， 2025， 187： 156856. doi：10.1016/j.cyto.2025.156856 . doi: 10.1016/j.cyto.2025.156856
[16]	SREBOTNIK KIRBIS I. State of the art and science of immunocytochemistry［J］. Acta Cytol， 2025， 69（1）： 51-59. doi：10.1159/000539634 . doi: 10.1159/000539634
[17]	LORETO C， CALTABIANO R. Immunohistochemical expression［J］. Appl Sci， 2021， 11（1）： 360. doi：10.3390/app11010360 . doi: 10.3390/app11010360
[18]	BOSCARO E， URBINO I， CATANIA F M， et al. Modern risk stratification of acute myeloid leukemia in 2023： Integrating established and emerging prognostic factors［J］. Cancers， 2023， 15（13）： 3512. doi：10.3390/cancers15133512 . doi: 10.3390/cancers15133512
[19]	CAO S， WANG Q， ZHU G. From chemotherapy to targeted therapy： Unraveling resistance in acute myeloid leukemia through genetic and non-genetic insights［J］. Int J Mol Sci， 2025， 26（9）： 4005. doi：10.3390/ijms26094005 . doi: 10.3390/ijms26094005
[20]	潘树耀，崔丽娟. 维奈克拉治疗急性髓系白血病的研究进展［J］. 宁夏医学杂志， 2025， 47（6）： 541-545. doi：10.13621/j.1001-5949.2025.06.0541 . doi: 10.13621/j.1001-5949.2025.06.0541
[21]	RAZMKHAH F， KIM S， LIM S， et al. S100A8 and S100A9 in hematologic malignancies： From development to therapy［J］. Int J Mol Sci， 2023， 24（17）： 13382. doi：10.3390/ijms241713382 . doi: 10.3390/ijms241713382
[22]	ZHOU H， ZHAO C， SHAO R， et al. The functions and regulatory pathways of S100A8/A9 and its receptors in cancers［J］. Front Pharmacol， 2023， 14： 1187741. doi：10.3389/fphar.2023. 1187741 . doi: 10.3389/fphar.2023. 1187741
[23]	ALLY F， CHEN X. Acute myeloid leukemia： Diagnosis and evaluation by flow cytometry［J］. Cancers， 2024， 16（22）： 3855. doi：10.3390/cancers16223855 . doi: 10.3390/cancers16223855

特征	完全缓解组CR（n = 44）	未缓解组NR（n = 36）	χ²/Z值	P值
年龄/岁	52（36，64）	43（31，59）	1.74	0.082
年龄分组/［例（%）］			1.85	0.174
≤ 65岁	34（77.27）	32（88.89）
65岁	10（22.73）	4（11.11）
性别/［例（%）］			0.02	0.875
男	24（54.55）	19（52.78）
女	20（45.45）	17（47.22）
骨髓原始细胞比例	34.15（15.62，61.8）	31.89（14.75，55.42）	0.86	0.390
白细胞计数/×10⁹/L	4.52（1.68，27.35）	3.61（0.94，9.86）	1.99	0.047
白细胞计数分组/［例（%）］			6.50	0.011
≤ 50 × 10⁹/L	32（72.73）	27（96.43）
50 × 10⁹/L	12（27.27）	1（3.57）
细胞遗传学风险/［例（%）］			5.57	0.018
正常核型	33（82.50）	12（54.55）
复杂核型	7（17.50）	10（45.45）
分子遗传学
FLT3?ITD/［例（%）］			3.91	0.048
阴性	29（72.50）	24（92.31）
阳性	11（27.50）	2（7.69）
NPM1/［例（%）］			6.74	0.009
阴性	27（69.23）	24（96.00）
阳性	12（30.77）	1（4.00）

Evaluation value of the proportion of S100A9-high-expressing cells in the malignant cell population for chemotherapy response and prognosis in patients with acute myeloid leukemia

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 23

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qiuhong LIN,Chunguang DONG,Jiahui HAN,Hongpeng DONG,Shujia ZHANG. The prognostic value of p16 protein expression in predicting outcomes of comprehensive treatment for locally advanced laryngeal and hypopharyngeal carcinoma [J]. The Journal of Practical Medicine, 2026, 42(9): 1545-1551.
[2]	Li XIANG,Yijuan JIA,Ping WANG,Yanqin LOU,Donghua WANG. The predictive value of sCD276，YKL-40，miR-152-5p and miR-193a-5p in the prognosis of patients with high-grade serous ovarian cancer [J]. The Journal of Practical Medicine, 2026, 42(8): 1428-1434.
[3]	Yahong NIE,Meiyu ZHAO,Chengyu SHI,Shan LIU. The relationship between serum miR-145， miR-934， AFP， TK1 levels and clinicopathological characteristics and prognosis in patients with primary liver cancer [J]. The Journal of Practical Medicine, 2026, 42(7): 1183-1191.
[4]	Fengxue DAI,Zhenfei WANG. Predictive analysis of serum COL10A1， miRNA-21 and miRNA-320c expression levels for peritoneal metastasis and prognosis of gastric cancer [J]. The Journal of Practical Medicine, 2026, 42(7): 1201-1207.
[5]	Chunming WU,Wen CHENG,Zhengguo ZHANG,Yan JIANG,Jun SUN. Relationship between CURB-65 score， serum IL-6， PCT/ALB ratio and prognosis in patients with severe pneumonia [J]. The Journal of Practical Medicine, 2026, 42(6): 923-929.
[6]	Bin YU,Jian ZHOU,Tian TIAN,Fusheng WANG. The efficacy of bevacizumab combined with chemotherapy in the treatment of postoperative patients with oligometastatic colorectal cancer and its impact on mpfs median progression-free survival [J]. The Journal of Practical Medicine, 2026, 42(5): 750-758.
[7]	Zhenggang WANG,Hui XIONG,Ting HE,Xiaojing LIU,Yanhua YE. Serum melatonin and IGFBP3 levels in the diagnosis and prognostic evaluation of age⁃related cataract [J]. The Journal of Practical Medicine, 2026, 42(5): 831-837.
[8]	Jinsong LI,Senxin HUA,Ludan HUANG,Qing SU. Changes in serum levels of NRG-1， CHIT1， Cx43， and MECP2 in patients with acute cerebral infarction and their relationship with severity and prognosis [J]. The Journal of Practical Medicine, 2026, 42(4): 691-697.
[9]	Jianhua JIAO,Ruixue MA,Honghong GU,Xing WU,Xiuli CAO. Evaluation value of sCD163， SHR， pro-ADM， PTX3 combined with score of chest CT on the condition and prognosis of elderly patients with stroke-related pneumonia [J]. The Journal of Practical Medicine, 2026, 42(3): 447-454.
[10]	Jianxia HUANG,Guoliang ZHANG,Jushan ZHANG,Yan WANG,Qing WU,Binzhang WU,Minghu DU,Yuxia WANG. The relationship between levels of serum MuC1， PINP， sFLC and clinical staging， immunophenotyping in patients with multiple myeloma and their predictive value for prognosis [J]. The Journal of Practical Medicine, 2026, 42(3): 504-510.
[11]	Wen LI,Haisheng HUANG,Bin HUANG,Li HAN. Expression correlation of PD⁃L1 and Her⁃2 in invasive urothelial carcinoma and their impact on prognosis [J]. The Journal of Practical Medicine, 2026, 42(2): 194-200.
[12]	Xin LIU,Hongrui ZHANG,Ying SHEN,Yuqiao DIAO,Tao FAN. Correlation of serum lncRNA THRIL， lncRNA NEAT1 with the severity and prognosis of neonatal pneumonia [J]. The Journal of Practical Medicine, 2026, 42(2): 327-333.
[13]	Min YANG,Hongbo QIAN,Dafa ZHANG,Yingjing GUI. Preoperative left ventricular end-systolic dimension predicts postoperative ejection fraction recovery trajectory and clinical outcomes in mitral regurgitation [J]. The Journal of Practical Medicine, 2026, 42(13): 2291-2299.
[14]	Wenqing ZHAO,Liuyuan LI,Chongjian ZHANG,Hailong QIU,Xiaofeng LI. Prognostic value of the Model for End-Stage Liver Disease Excluding International Normalized Ratio（MELD-XI） score for long-term all-cause mortality in elderly patients following cardiac valve surgery [J]. The Journal of Practical Medicine, 2026, 42(12): 2091-2097.
[15]	Ting ZHU,Xiaowen ZONG,Yaping SUN,Zhaohui LUAN. Value of combined detection of serum PAX8， ENO1， HE4 and NRP-2 in prognosis evaluation of endometrial cancer [J]. The Journal of Practical Medicine, 2026, 42(12): 2136-2143.